37 results about "Differentiation Agents" patented technology

The present application describes various applications of the non-expansion protocol for the preparation of an injectable autologous cell mixture of the present invention that can be used to prevent symptoms in a number of indications. Cells are isolated from surgically derived tissue and are at least partially disaggregated from each other. The heterologous cell mixture is mixed with growth factors, differentiation agents, extracellular matrix proteins and / or microspheres and injected into the patient without cell expansion. The harvesting of tissue, cell isolation, and injection are performed within a single surgical procedure lasting only minutes to hours.

The invention provides icariin application in inducing stem cell in vitro orientation differentiates to several single type cells. The stem cell said includes embryonic stem cell, nerve stem cell and marrow mesenchyme stem cell. The single type cell includes nerve cell, bone cell, islet cells and endothelial cell. This invention also relates to application of the single type cell in preparing medicine of stem cell transplant curing nerve degenerative diseases, and its application in preparing cell differentiation agent that used to repair recovery injured nerve tissue, and its application in high efficiency drug effect screening model rebuilding and initial screening and estimating by using the model. The new applications of the icariin is extended in this invention, the fact of icariin contains pharmacy activity clarified, so it provides material basis for Chinese traditional medicine prevention and cure effect. The clarifying of drug effect mechanism provides reference for new medicine Chinese metical modern development with self-owned intellectual property right.

The invention relates to an acceleration sensor for detecting inertia forces, in which several separable and non-miscible media are stored in a receptacle and from at least one interphase between the media. Differentiation agents are provided to distinguish dynamic changes of position of the interphase from static changes of position, and evaluation agents evaluate the dynamic changes of position for the gradual determination of acceleration. An acceleration sensor that reacts sensitively to acceleration and deceleration, but which emits no signal when the sensor is rotated away from zero-position is thus created.

The invention provides a method of inducing human embryon stem cells as liver cells out of body via embryoid bodies using DMSO as dissmilation starter solution and allying nourish factors of liver cell containing niacinamide. The liver cells obtained by the method is also provided, which originating from human embryon stem cells with conformation as normal liver cell and subcellular structure as bile capillary, gene products for expressing differentia of the liver cell such as G6PC, LST, CPS1, CYP7A1, FIX etc., and can perform function of mature liver cells. The invention also provides such liver cells having founctions as liver cells or liver transpalnt, liver sick treating, artifical liver forming, medicine identifying and selecting, toxicity testing and toxicity research.

It has been found that when pluripotent stem cells are cultured in the presence of hepatocyte differentiating agents, a population of cells is derived that has a remarkably high proportion of cells with a stem cell phenotype. In one example, human embryonic stem cells are allowed to form embryoid bodies and then mixed with the differentiation agent n-butyrate, optionally supplemented with maturation factors. In another example, n-butyrate is added to human embryonic stem cells in feeder-free culture. A remarkably homogeneous population of cells was obtained in both methods, consisting primarily of cells with morphological characteristics of hepatocytes, expressing characteristic surface markers of hepatocytes, and also possessing enzymatic and biosynthetic roles important for liver function. Since hepatocytes readily proliferate in culture, this system provides a rich source of hepatocyte lineage cells for various uses, such as drug screening and supplementation of liver function in clinical therapy.

The present invention provides a method of inducing undifferentiated cells into induced osteoblasts. The method includes: A) a step of providing an induced osteoblast differentiation inducing agent obtained by culturing chondrocytes capable of hypertrophication in a differentiation agent producing medium containing dexamethasone, β-glycerophosphate, ascorbic acid and a serum component; and B) a step of culturing the undifferentiated cells in an undifferentiated cell culture medium containing the induced osteoblast differentiation inducing agent and a medium component, to differentiate the undifferentiated cells into the induced osteoblasts.

A method of preparing neural precursor cells by exposing pluripotent stem cells or neural stem cells to a differentiation agent. The agent is a pyridine analog, which in preferred embodiments is a phenylethynyl-substituted or phenylazo-substituted pyridine. In other embodiments, a method of enhancing neural precursor cell survival is provided in which the survival is enhanced by exposure to the pyridine analog. In further embodiments, a method of preparing neuronal cells is provided in which pluripotent or neural stem cells exposed to the pyridine analog are then incubated without the pyridine analog, resulting in differentiation into neurons, astrocytes and oligodendrocytes. These methods may be used in toxicological screens, e.g., to evaluate the neurotoxicity of a test compound.

The present invention provides an agent obtainable by culturing a chondrocyte capable of hypertrophication in a differentiation agent producing medium, wherein the differentiation agent producing medium comprises at least one conventional osteoblast differentiation component selected from the group consisting of glucocorticoid, β-glycerophosphate and ascorbic acid. The differentiation agent producing medium may comprise all of glucocorticoid, β-glycerophosphate and ascorbic acid.

A method of preparing neural precursor cells by exposing pluripotent stem cells or neural stem cells to a differentiation agent. The agent is a pyridine analog, which in preferred embodiments is a phenylethynyl-substituted or phenylazo-substituted pyridine. In other embodiments, a method of enhancing neural precursor cell survival is provided in which the survival is enhanced by exposure to the pyridine analog. In further embodiments, a method of preparing neuronal cells is provided in which pluripotent or neural stem cells exposed to the pyridine analog are then incubated without the pyridine analog, resulting in differentiation into neurons, astrocytes and oligodendrocytes. These methods may be used in toxicological screens, e.g., to evaluate the neurotoxicity of a test compound.

The invention belongs to the field of regenerative medicine and pharmacology, relates to an application of a double hydrogen flavonoid small molecule compound, and particularly relates to a new application of naringin in promoting proliferation and differentiation of a neural stem cell. The invention is characterized by relating to an application of the naringin in medicament for neural stem cell transplantation in the treatment of neurodegenerative diseases, an application of the naringin in repairing damaged nerve tissues and preparation a function-reconstructable nerve nutriment and cell differentiation agent, and an application of the naringin in constructing an efficient medicament screening model and applying the efficient medicament screening model to preliminary screening and evaluation of the medicament efficacy. The invention confirms the new pharmacological activity of the naringin, establishes an application foundation in stem cell transplantation (SCT), and provides new thoughts for developing new medicaments with independent intellectual property rights.

The invention provides application of ZDHHC21 genes in preparation of leukemia induced differentiation therapy drugs, and application of polypeptides targeting the DHHC21 genes, small molecule inhibitors and interfering siRNAs in preparation of leukemia induced differentiation agents. Research shows that as the ZDHHC21 amount is reduced by the RNA interfering technology, the proliferation of leukemia HL60 and NB4 cells is significantly inhibited, the expression of cell surface differentiation-specific antigens CD11b is significantly increased, the reduction ability of NBT of the cells is enhanced, and the ratio of nucleus to cytoplasm in the cells is reduced, the shapes of cell nuclei are changed into U shapes or half-moon shapes. Down-regulation of ZDHHC21 can effectively induce the differentiation of the human leukemia cells, a new direction is provided for the development of treatment drugs for leukemia, a new therapeutic target is provided for induction differentiation therapy of leukemia, and a new research field is opened up for the treatment of leukemia, the improvement of the treatment effect and the improvement of drug resistance.

The invention belongs to the field of regenerative medicine and pharmacology, relates to an application of a double hydrogen flavonoid small molecule compound, and particularly relates to a new application of naringin in promoting proliferation and differentiation of a neural stem cell. The invention is characterized by relating to an application of the naringin in medicament for neural stem cell transplantation in the treatment of neurodegenerative diseases, an application of the naringin in repairing damaged nerve tissues and preparation a function-reconstructable nerve nutriment and cell differentiation agent, and an application of the naringin in constructing an efficient medicament screening model and applying the efficient medicament screening model to preliminary screening and evaluation of the medicament efficacy. The invention confirms the new pharmacological activity of the naringin, establishes an application foundation in stem cell transplantation (SCT), and provides new thoughts for developing new medicaments with independent intellectual property rights.

The present invention relates to a pharmaceutical composition for the treatment and prevention of cancer and the preparation method thereof, especially to a cell differentiation agent named CDA-II which is prepared by reverse phase chromatography of fresh human urine. The pharmaceutical composition is effective for the treatment and prevention of cancer. The active components in CDA-II contain differentiation inducers, differentiation helper inducers and an anticachexia agent, which act cooperatively to achieve the best therapeutic effect.

The present invention provides therapy and methods for the treatment and prevention of diseases of cell proliferation such as cancer, benign tumors, and viral diseases such as HIV-AIDS, hepatitis B, hepatitis C and cirrhosis. The methods of this invention consist of the administration to a patient of a combination of effective amounts of agents capable of eradicating the neoplastic cells, while sparing the non-neoplastic cells from cytotoxic side-effects. The agents co-administered in therapeutically effective amounts are: chemotherapeutic agents, apoptotic agents, anti-angiogenic agents, cell differentiation agents, immunomodulating agents, antioxidants, vitamins, microelements, enzymes and natural extracts.

The invention discloses a special-effect stem-cell in-vitro induction technology. The special-effect stem-cell in-vitro induction technology includes: separating and culturing human umbilical cord stem cells, to be more specific, using the human umbilical cord stem cells, taking human umbilical cord Wharton's jelly in a sterile manner, collecting cell suspension, changing the suspension when primary culture is performed for 24 hours, and changing the suspension when the primary culture is performed for 48 hours; performing primary culture for 7 days, digesting with trypsin if cell flocking is observed and then performing passage into a new bottle, and discarding suspended cells, wherein most of the human umbilical cord stem cells firmly attach to the bottle wall; adding a whole culture medium to start passage culture, changing the culture liquid every 3 days, and performing continuous passage for 3 generations; performing in-vitro human umbilical cord stem cell induction, to be more specific, selecting the stem cells with appropriate passage time and within 3 generations, changing the liquid, adding an induction differentiation agent 5-azacytidine, adding a liver cell growth factor HGF, basic growth factors EGF+bFGF and a stem cell factor SGF, and performing in-vitro induction for 24 hours. By the latest-generation in-vitro induction technology, the target homing rate of the in-vivo stem cells is 100%.

The invention relates to a multifunctional growth regulator composition for peach trees and belongs to the field of plant growth regulation. The multifunctional growth regulator composition comprises, by weight, 4-11 parts of gibberellin, 5-10 parts of pimacol, 8-22 parts of diethyl aminoethyl hexanoate, 20-40 parts of auxiliaries and 33-50 parts of additives, wherein the auxiliaries refer to one or more of a fruit expander, a sugar increasing substance, a drought-resistant and water-retaining agent, a flower bud differentiation agent, ferrous sulfate, magnesium sulfate, vitamins and amino acids, and the additives refer to one or more of calcium carbonate, bentonite and kaolin. The multifunctional growth regulator composition for the peach trees has the effects on resisting adverse factors and synergy through synergism through all components and has a variety of efficacy without side effect.

The invention relates to the technical field of stem cells, in particular to a stem cell preparation for treating knee joint degenerative change and a preparation method thereof. A DMEM LG / F12 basic culture medium, 10% human platelet lysis buffer and 10g / L basic fibroblast growth factors are adopted as culture solutions; 10nM of dexamethasone, 25mu g / mL of vitamin C and 2mM of beta-glycerophosphate are used as chondrogenesis induced differentiation agents, so that the culture of the umbilical cord mesenchymal stem cells is successfully realized. The serum-free culture solution used in the invention can achieve the same culture effect as a culture solution containing serum in a contrast; due to the fact that the used culture solution is clear in component, compared with a culture solution containing fetal calf serum, introduction of animal exogenous substances is avoided, and risks caused by serum to cell culture can be avoided to the maximum extent.

The present invention relates to stem cells obtained by culturing monocytes in the presence of (i) M-CSF and (ii) at least one member selected from the group consisting of ganglioside and water-soluble plant-derived extract, thereby dedifferentiating the monocytes; a therapeutic agent for treating damaged cells, tissues or organs; a cell drug agent; a method of producing stem cells, a culture medium for dedifferentiating monocytes; a dedifferentiation inducing agent; a cell drug kit; a kit for producing dedifferentiated cells; and a pharmaceutical composition.

The present invention relates to a pharmaceutical composition for the treatment and prevention of cancer and the preparation method thereof, especially to a cell differentiation agent named CDA-II which is prepared by reverse phase chromatography of fresh human urine. The pharmaceutical composition is effective for the treatment and prevention of cancer. The active components in CDA-II contain differentiation inducers, differentiation helper inducers and an anticachexia agent, which act cooperatively to achieve the best therapeutic effect.

The invention discloses application of an AK2 gene in preparation of a leukemia induced differentiation treatment medicine. According to the invention, the differentiation of leukemia cells can be directly induced by reducing the expression of AK2 by using an siRNA interference technology. Therefore, it is proposed for the first time that the AK2 gene is a key gene for leukemia induced differentiation treatment, siRNAs molecules of the AK2 can be used as a leukemia induced differentiation agent, a new treatment target is provided for induced differentiation treatment of leukemia, and the AK2 gene plays an important role in treatment of leukemia. The invention provides possibilities for preparing novel drugs for induced differentiation of leukemia, improving the curative effect of leukemia patients and improving drug resistance and related prognosis conditions.

A pear tree plant growth regulator composition is composed of the following components in parts by weight: 10-20 parts of diethylaminoethyl hexanoate, 5-10 parts of brassinolide, 5-10 parts of sodium naphthalene acetate, 20-40 parts of an auxiliary agent and 33-50 parts of an additive; the auxiliary agent is one or more of a fruit swelling agent, a sugar increasing agent, a drought resistance and water conservation agent, a flower bud differentiation agent, ferrous sulfate, magnesium sulfate, vitamin and amino acid, and the additive is one or more of calcium carbonate, bentonite and kaolin; the regulator composition also includes 4-10 parts by weight of forchlorfenuron. The regulator composition not only can promote growth and development of roots, stems, leaves, flowers and fruits of pear trees, improve fruit setting and promote green big fruits to grow, but also can make new shoots grow healthy and vigorous and grow non-excessive and promote more and large leaves with high efficient value to grow; and the regulator composition not only ensures that the fruits rapidly grow, but also allows more nutrients to be remained so as to ensure the formation of more large flower buds, large thickening amount of branches and trunks and healthy and vigorous growth of root systems, so as to form large root systems having a large number of absorbing roots.

The present invention concerns preventative, therapeutic, and diagnostic methods and compositions involving UC markers, such as UC 28, for cancer. It includes methods and compositions for targeting cancer cells using a differentiation agent in combination with a therapeutic agent targeted to cells that differentially express a UC marker after exposure to the differentiation agent. The invention also includes methods of inducing immune responses against UC markers, as well as antibodies that recognize UC markers, which may be employed for therapeutic and diagnostic methods.

The invention provides in certain embodiments, a method of generating a re-programmed differentiated epithelial cell comprising (a) contacting a non-stem somatic cell obtained from a subject with an effective amount of a de-differentiation agent to form a de-differentiated cell, and (b) transfecting the de-differentiated cell with an expression cassette comprising a promoter operably linked to a nucleic acid encoding a conversion agent to form a re-programmed differentiated cell. The invention also provides in certain embodiments, a method of generating a re-programmed differentiated epithelial cell comprising (a) contacting a non-stem somatic cell obtained from a subject with an effective amount of a de-differentiation agent to form a de-differentiated cell, and (b) contacting the de-differentiated cell with a conversion agent to form a re-programmed differentiated cell. The invention provides in certain embodiments, re-programmed differentiated epithelial cells, and methods of using these re-programmed differentiated epithelial cells to repair or re-generate tissue in vivo.

The invention provides a single type nerve cell which is formed by in vitro directed differentiation of sobavachin-induced stem cells (comprising embryonic stem cells, neural stem cells and bone marrow mesenchymal stem cells). The single type nerve cell is applied in the preparation of drugs used for stem cell transplantation therapy of neurodegenerative diseases, in the preparation of cell differentiation agents used for repairing and reconstructing of damaged nerve cells and is also applied in the construction of a efficacy screening and evaluation model. The invention develops a new usage of the isobavachin, provides a physical basis for the prevention and treatment functions of the isobavachin traditional Chinese medicine and also provides a basis for the drug regulation and control regenerative medicine or the tissue engineering.